TY - JOUR A1 - Isles, Anthony R. A1 - Ingason, Andrés A1 - Lowther, Chelsea A1 - Walters, James A1 - Gawlick, Micha A1 - Stöber, Gerald A1 - Rees, Elliott A1 - Martin, Joanna A1 - Little, Rosie B. A1 - Potter, Harry A1 - Georgieva, Lyudmila A1 - Pizzo, Lucilla A1 - Ozaki, Norio A1 - Aleksic, Branko A1 - Kushima, Itaru A1 - Ikeda, Masashi A1 - Iwata, Nakao A1 - Levinson, Douglas F. A1 - Gejman, Pablo V. A1 - Shi, Jianxin A1 - Sanders, Alan R. A1 - Duan, Jubao A1 - Willis, Joseph A1 - Sisodiya, Sanjay A1 - Costain, Gregory A1 - Werge, Thomas M. A1 - Degenhardt, Franziska A1 - Giegling, Ina A1 - Rujescu, Dan A1 - Hreidarsson, Stefan J. A1 - Saemundsen, Evald A1 - Ahn, Joo Wook A1 - Ogilvie, Caroline A1 - Girirajan, Santhosh D. A1 - Stefansson, Hreinn A1 - Stefansson, Kari A1 - O'Donovan, Michael C. A1 - Owen, Michael J. A1 - Bassett, Anne A1 - Kirov, George T1 - Parental Origin of Interstitial Duplications at 15q11.2-q13.3 in Schizophrenia and Neurodevelopmental Disorders JF - PLoS Genetics N2 - Duplications at 15q11.2-q13.3 overlapping the Prader-Willi/Angelman syndrome (PWS/AS) region have been associated with developmental delay (DD), autism spectrum disorder (ASD) and schizophrenia (SZ). Due to presence of imprinted genes within the region, the parental origin of these duplications may be key to the pathogenicity. Duplications of maternal origin are associated with disease, whereas the pathogenicity of paternal ones is unclear. To clarify the role of maternal and paternal duplications, we conducted the largest and most detailed study to date of parental origin of 15q11.2-q13.3 interstitial duplications in DD, ASD and SZ cohorts. We show, for the first time, that paternal duplications lead to an increased risk of developing DD/ASD/multiple congenital anomalies (MCA), but do not appear to increase risk for SZ. The importance of the epigenetic status of 15q11.2-q13.3 duplications was further underlined by analysis of a number of families, in which the duplication was paternally derived in the mother, who was unaffected, whereas her offspring, who inherited a maternally derived duplication, suffered from psychotic illness. Interestingly, the most consistent clinical characteristics of SZ patients with 15q11.2-q13.3 duplications were learning or developmental problems, found in 76% of carriers. Despite their lower pathogenicity, paternal duplications are less frequent in the general population with a general population prevalence of 0.0033% compared to 0.0069% for maternal duplications. This may be due to lower fecundity of male carriers and differential survival of embryos, something echoed in the findings that both types of duplications are de novo in just over 50% of cases. Isodicentric chromosome 15 (idic15) or interstitial triplications were not observed in SZ patients or in controls. Overall, this study refines the distinct roles of maternal and paternal interstitial duplications at 15q11.2-q13.3, underlining the critical importance of maternally expressed imprinted genes in the contribution of Copy Number Variants (CNVs) at this interval to the incidence of psychotic illness. This work will have tangible benefits for patients with 15q11.2-q13.3 duplications by aiding genetic counseling. KW - interstitial duplications KW - schizophrenia KW - developmental delay KW - autism spectrum disorder KW - parental origin KW - genetics Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-166706 VL - 12 IS - 5 ER - TY - JOUR A1 - van de Kerkhof, Nora WA A1 - Fekkes, Durk A1 - van der Heijden, Frank MMA A1 - Hoogendijk, Witte JG A1 - Stöber, Gerald A1 - Egger, Jos IM A1 - Verhoeven, Willem MA T1 - Cycloid psychoses in the psychosis spectrum: evidence for biochemical differences with schizophrenia JF - Neuropsychiatric Disease and Treatment N2 - Cycloid psychoses (CP) differ from schizophrenia regarding symptom profile, course, and prognosis and over many decades they were thought to be a separate entity within the psychosis spectrum. As to schizophrenia, research into the pathophysiology has focused on dopamine, brain-derived neurotrophic factor, and glutamate signaling in which, concerning the latter, the N-methyl-d-aspartate receptor plays a crucial role. The present study aims to determine whether CP can biochemically be delineated from schizophrenia. Eighty patients referred for psychotic disorders were assessed with the Comprehensive Assessment of Symptoms and History, and (both at inclusion and after 6 weeks of antipsychotic treatment) with the Positive and Negative Syndrome Scale and Clinical Global Impression. From 58 completers, 33 patients were diagnosed with schizophrenia and ten with CP according to the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, and Leonhard criteria, respectively. Fifteen patients were diagnosed with other disorders within the psychosis spectrum. At both time points, blood levels of the dopamine metabolite homovanillic acid, brain-derived neurotrophic factor, and amino acids related to glutamate neurotransmission were measured and compared with a matched control sample. Patients with CP showed a significantly better response to antipsychotic treatment as compared to patients with schizophrenia. In CP, glycine levels were elevated and tryptophan levels were lowered as compared to schizophrenia. Glutamate levels were increased in both patient groups as compared to controls. These results, showing marked differences in both treatment outcome and glutamate-related variable parameters, may point at better neuroplasticity in CP, necessitating demarcation of this subgroup within the psychosis spectrum. KW - cycloid psychoses KW - schizophrenia KW - glutamate KW - glycine KW - tryptophan KW - neuroplasticity Y1 - 2016 U6 - http://nbn-resolving.de/urn/resolver.pl?urn:nbn:de:bvb:20-opus-166255 VL - 12 ER -